The Department for Health and Social Care has asked NICE to conduct an appraisal of duvelisib for treating relapsed follicular lymphoma after at least 2 systemic therapies.
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.